Stemline Therapeutics Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Stemline Therapeutics's estimated annual revenue is currently $500k per year.(i)
  • Stemline Therapeutics received $59.5M in venture funding in January 2018.
  • Stemline Therapeutics's estimated revenue per employee is $1,166
  • Stemline Therapeutics's total funding is $107.1M.

Employee Data

  • Stemline Therapeutics has 429 Employees.(i)
  • Stemline Therapeutics grew their employee count by 63% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-701, and SL-801. A Phase 2 potentially pivotal trial with SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range of hematologic cancers, is enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) for which it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Data from this ongoing trial have demonstrated high overall response rates (ORR), with multiple complete responses (CRs). Patients are being followed for response duration and outcomes, and new patients continue to enroll into the study. In addition, ongoing Phase 2 trials with SL-401 are currently enrolling patients with additional malignancies including acute myeloid leukemia (AML) in remission with high risk for relapse including minimal residual disease (MRD) and advanced, high risk myeloproliferative neoplasms (MPN) of unmet medical need. A Phase 1/2 trial in relapsed/refractory multiple myeloma with SL-401 in combination with standard therapies is also enrolling patients. A Phase 2 trial with SL-701, an immunotherapy designed to activate the immune system to attack tumors, in adult patients with second-line glioblastoma multiforme (GBM) is ongoing. A Phase 1 trial with SL-801, a novel oral small molecule reversible inhibitor of XPO1, is currently enrolling patients with advanced solid tumors. For more information about Stemline Therapeutics, visit

keywords:Biotechnology,Healthcare,Marketing,Medical Diagnostics,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Stemline Therapeutics News

2022-04-17 - Global Baculoviral IAP Repeat Containing Protein 5 Market ...

... Bioneer Corp; Boehringer Ingelheim GmbH; Immunovaccine Inc; MimiVax LLC; Optimum Therapeutics LLC; Polyplus-Transfection SA; Stemline Therapeutics Inc...

2022-04-17 - Cancer Stem Cells Market to Witness Huge Growth by 2027 ...

... Therapies specific to Targeting Cancer Stem Cells are anticipated to ... Lonza Group (Switzerland) , Stemline Therapeutics, Inc.(United...

2022-04-06 - Hypereosinophilic Syndrome Market: The Benralizumab ...

Novel targeted therapies, including tyrosine kinase inhibitors and monoclonal ... Ltd., Knopp Biosciences LLC., Stemline Therapeutics, Inc.,...

2020-05-04 - Italy’s Menarini Group to acquire Stemline Therapeutics for $677M

Shares of Stemline were up 153.7% on the Nasdaq by late morning following the news. Menarini is a privately held company. Stemline won Food and Drug Administration approval in December 2018 for Elzonris (tagraxofusp-erzs), a drug used to treat blastic plasmacytoid dendritic cell neoplasm, or BP ...

2019-09-08 - Checking the True Picture for Stemline Therapeutics, Inc ...

On Monday, shares of Stemline Therapeutics, Inc. (NASDAQ:STML) marked $11.32 per share versus a previous $10.99 closing price.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Stemline Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-01-09$59.8MUndisclosedJefferies LLCArticle
2018-01-25$59.5MUndisclosedJ.P. Morgan Securities LLCArticle